You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameMetipranolol
Accession NumberDB01214  (APRD00668)
TypeSmall Molecule
GroupsApproved
DescriptionA beta-adrenergic antagonist effective for both beta-1 and beta-2 receptors. It is used as an antiarrhythmic, antihypertensive, and antiglaucoma agent. [PubChem]
Structure
Thumb
Synonyms
(+-)-Metipranolol
Acetic acid 4-(2-hydroxy-3-isopropylamino-propoxy)-2,3,6-trimethyl-phenyl ester
Metipranolol
Metipranololum
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
MetipranololSolution / drops3 mg/mLOphthalmicFalcon Pharmaceuticals, Ltd.2001-08-09Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
BetanolNot Available
DisoratNot Available
OptiPranololNot Available
TrimepranolNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Metipranolol hydrochloride
Thumb
  • InChI Key: BLWNYSZZZWQCKO-UHFFFAOYNA-N
  • Monoisotopic Mass: 345.170686096
  • Average Mass: 345.862
DBSALT000806
Categories
UNIIX39AL81KEB
CAS number22664-55-7
WeightAverage: 309.4006
Monoisotopic: 309.194008357
Chemical FormulaC17H27NO4
InChI KeyBQIPXWYNLPYNHW-UHFFFAOYSA-N
InChI
InChI=1S/C17H27NO4/c1-10(2)18-8-15(20)9-21-16-7-11(3)17(22-14(6)19)13(5)12(16)4/h7,10,15,18,20H,8-9H2,1-6H3
IUPAC Name
4-{2-hydroxy-3-[(propan-2-yl)amino]propoxy}-2,3,6-trimethylphenyl acetate
SMILES
CC(C)NCC(O)COC1=C(C)C(C)=C(OC(C)=O)C(C)=C1
Pharmacology
IndicationIndicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open angle glaucoma.
Structured Indications
PharmacodynamicsMetipranolol is a beta1 and beta2 (non-selective) adrenergic receptor-blocking agent that does not have significant intrinsic sympathomimetic, direct myocardial depressant, or local anesthetic (membrane-stabilizing) activity. Metipranolol is indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. Metipranolol, when applied topically to the eye, has the action of reducing elevated, as well as normal, intraocular pressure, whether or not accompanied by glaucoma. Elevated intraocular pressure is a major risk factor in the pathogenesis of glaucomatous visual field loss and optic nerve damage. Metipranolol reduces intraocular pressure with little or no effect on pupil size or accommodation in contrast to the miosis which cholinergic agents are known to produce.
Mechanism of actionAlthough it is known that metipranolol binds the beta1 and beta2 adrenergic receptors, the mechanism of metipranolol's action is not known. It has no significant intrinsic sympathomimetic activity, and has only weak local anesthetic (membrane-stabilizing) and myocardial depressant activity. It appears that the ophthalmic beta-adrenergic blocking agents reduce aqueous humor production, as demonstrated by tonography and fluorophotometry. A slight increase in aqueous humor outflow may be an additional mechanism.
TargetKindPharmacological actionActionsOrganismUniProt ID
Beta-1 adrenergic receptorProteinyes
antagonist
HumanP08588 details
Beta-2 adrenergic receptorProteinyes
antagonist
HumanP07550 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Metipranolol Action PathwayDrug actionSMP00667
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,10-Phenanthroline1,10-Phenanthroline may increase the bradycardic activities of Metipranolol.Experimental
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Metipranolol.Experimental
AcebutololThe risk or severity of adverse effects can be increased when Acebutolol is combined with Metipranolol.Approved
AceclofenacAceclofenac may decrease the antihypertensive activities of Metipranolol.Approved
AcepromazineAcepromazine may increase the hypotensive activities of Metipranolol.Approved, Vet Approved
AceprometazineAceprometazine may increase the hypotensive activities of Metipranolol.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Metipranolol is combined with Acetazolamide.Approved, Vet Approved
AcetohexamideMetipranolol may increase the hypoglycemic activities of Acetohexamide.Withdrawn
AcetovanilloneAcetovanillone may decrease the antihypertensive activities of Metipranolol.Investigational
AcetylcholineThe risk or severity of adverse effects can be increased when Metipranolol is combined with Acetylcholine.Approved
AcetyldigitoxinMetipranolol may increase the bradycardic activities of Acetyldigitoxin.Approved
Acetylsalicylic acidAcetylsalicylic acid may decrease the antihypertensive activities of Metipranolol.Approved, Vet Approved
AdapaleneAdapalene may decrease the antihypertensive activities of Metipranolol.Approved
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Metipranolol.Approved
AlfentanilAlfentanil may increase the bradycardic activities of Metipranolol.Approved, Illicit
AlfuzosinAlfuzosin may increase the hypotensive activities of Metipranolol.Approved, Investigational
AlimemazineAlimemazine may increase the hypotensive activities of Metipranolol.Approved, Vet Approved
AliskirenThe risk or severity of adverse effects can be increased when Metipranolol is combined with Aliskiren.Approved, Investigational
AlprenololAlprenolol may increase the hypotensive activities of Metipranolol.Approved, Withdrawn
AmbenoniumAmbenonium may increase the bradycardic activities of Metipranolol.Approved
AmbrisentanMetipranolol may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmifostineMetipranolol may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Metipranolol.Approved
AmiodaroneAmiodarone may increase the bradycardic activities of Metipranolol.Approved, Investigational
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Metipranolol.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Metipranolol.Approved, Illicit
AmodiaquineThe metabolism of Metipranolol can be decreased when combined with Amodiaquine.Approved
Amphotericin BThe risk or severity of adverse effects can be increased when Metipranolol is combined with Amphotericin B.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Metipranolol is combined with Amyl Nitrite.Approved
AnisodamineAnisodamine may decrease the antihypertensive activities of Metipranolol.Investigational
AntipyrineAntipyrine may decrease the antihypertensive activities of Metipranolol.Approved
AnvirzelMetipranolol may increase the bradycardic activities of Anvirzel.Investigational
ApomorphineThe risk or severity of adverse effects can be increased when Metipranolol is combined with Apomorphine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Apraclonidine is combined with Metipranolol.Approved
ApremilastApremilast may decrease the antihypertensive activities of Metipranolol.Approved, Investigational
ArecolineThe risk or severity of adverse effects can be increased when Metipranolol is combined with Arecoline.Experimental
AripiprazoleAripiprazole may increase the hypotensive activities of Metipranolol.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Metipranolol is combined with Arotinolol.Approved
Arsenic trioxideThe risk or severity of adverse effects can be increased when Metipranolol is combined with Arsenic trioxide.Approved, Investigational
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Metipranolol.Approved
AzapropazoneAzapropazone may decrease the antihypertensive activities of Metipranolol.Withdrawn
AzelastineAzelastine may decrease the antihypertensive activities of Metipranolol.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Metipranolol is combined with Azilsartan medoxomil.Approved
BalsalazideBalsalazide may decrease the antihypertensive activities of Metipranolol.Approved, Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Metipranolol.Experimental
BarbitalBarbital may increase the hypotensive activities of Metipranolol.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Metipranolol is combined with Barnidipine.Approved
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Metipranolol.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Metipranolol.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Metipranolol.Withdrawn
BenoxaprofenBenoxaprofen may decrease the antihypertensive activities of Metipranolol.Withdrawn
BepridilMetipranolol may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BeractantMetipranolol may increase the bradycardic activities of Beractant.Approved
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Metipranolol.Approved
BethanecholThe risk or severity of adverse effects can be increased when Metipranolol is combined with Bethanechol.Approved
BethanidineBethanidine may increase the hypotensive activities of Metipranolol.Approved
Betulinic AcidBetulinic Acid may decrease the antihypertensive activities of Metipranolol.Investigational
BimatoprostBimatoprost may increase the hypotensive activities of Metipranolol.Approved, Investigational
BisoprololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Metipranolol.Approved
BL-1020BL-1020 may increase the hypotensive activities of Metipranolol.Investigational
BortezomibThe risk or severity of adverse effects can be increased when Metipranolol is combined with Bortezomib.Approved, Investigational
BosentanBosentan may increase the hypotensive activities of Metipranolol.Approved, Investigational
BretyliumBretylium may increase the bradycardic activities of Metipranolol.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Metipranolol.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Metipranolol.Approved
BromfenacBromfenac may decrease the antihypertensive activities of Metipranolol.Approved
BromocriptineMetipranolol may increase the vasoconstricting activities of Bromocriptine.Approved, Investigational
BucillamineBucillamine may decrease the antihypertensive activities of Metipranolol.Investigational
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Metipranolol.Approved
BupivacaineThe serum concentration of Bupivacaine can be increased when it is combined with Metipranolol.Approved, Investigational
BupranololMetipranolol may increase the hypotensive activities of Bupranolol.Approved
CabergolineMetipranolol may increase the vasoconstricting activities of Cabergoline.Approved
CalfactantMetipranolol may increase the bradycardic activities of Calfactant.Approved
CanagliflozinThe risk or severity of adverse effects can be increased when Metipranolol is combined with Canagliflozin.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Metipranolol.Approved
CandoxatrilCandoxatril may increase the hypotensive activities of Metipranolol.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Metipranolol.Approved
CarbacholThe risk or severity of adverse effects can be increased when Metipranolol is combined with Carbachol.Approved
CarbetocinThe risk or severity of adverse effects can be increased when Metipranolol is combined with Carbetocin.Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Metipranolol.Withdrawn
CarprofenCarprofen may decrease the antihypertensive activities of Metipranolol.Approved, Vet Approved, Withdrawn
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with Metipranolol.Approved
CarvedilolThe risk or severity of adverse effects can be increased when Carvedilol is combined with Metipranolol.Approved, Investigational
CastanospermineCastanospermine may decrease the antihypertensive activities of Metipranolol.Experimental
CelecoxibCelecoxib may decrease the antihypertensive activities of Metipranolol.Approved, Investigational
CeliprololMetipranolol may increase the hypotensive activities of Celiprolol.Approved, Investigational
CeritinibMetipranolol may increase the bradycardic activities of Ceritinib.Approved
CevimelineThe risk or severity of adverse effects can be increased when Metipranolol is combined with Cevimeline.Approved
ChloroquineThe metabolism of Metipranolol can be decreased when combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Metipranolol.Approved, Vet Approved
ChlorpromazineChlorpromazine may increase the hypotensive activities of Metipranolol.Approved, Vet Approved
ChlorpropamideMetipranolol may increase the hypoglycemic activities of Chlorpropamide.Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Metipranolol.Approved
CilazaprilThe risk or severity of adverse effects can be increased when Metipranolol is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Metipranolol is combined with Cilnidipine.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Metipranolol is combined with Clevidipine.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Metipranolol is combined with Clofarabine.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Metipranolol is combined with Clomipramine.Approved, Vet Approved
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Metipranolol.Approved
ClonixinClonixin may decrease the antihypertensive activities of Metipranolol.Approved
ClozapineThe risk or severity of adverse effects can be increased when Metipranolol is combined with Clozapine.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Metipranolol is combined with Conivaptan.Approved, Investigational
CoumaphosCoumaphos may increase the bradycardic activities of Metipranolol.Vet Approved
CrizotinibMetipranolol may increase the bradycardic activities of Crizotinib.Approved
CryptenamineCryptenamine may increase the hypotensive activities of Metipranolol.Approved
CurcuminCurcumin may decrease the antihypertensive activities of Metipranolol.Investigational
CyclothiazideCyclothiazide may increase the hypotensive activities of Metipranolol.Approved
D-LimoneneD-Limonene may decrease the antihypertensive activities of Metipranolol.Investigational
DapagliflozinThe risk or severity of adverse effects can be increased when Metipranolol is combined with Dapagliflozin.Approved
DapoxetineThe serum concentration of Metipranolol can be increased when it is combined with Dapoxetine.Investigational
DebrisoquinMetipranolol may increase the hypotensive activities of Debrisoquin.Approved
DecamethoniumDecamethonium may increase the bradycardic activities of Metipranolol.Approved
DemecariumDemecarium may increase the bradycardic activities of Metipranolol.Approved
DeserpidineMetipranolol may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Metipranolol is combined with Desflurane.Approved
DeslanosideMetipranolol may increase the bradycardic activities of Deslanoside.Approved
DesvenlafaxineThe serum concentration of Metipranolol can be increased when it is combined with Desvenlafaxine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Metipranolol.Approved, Vet Approved
DiazoxideDiazoxide may increase the hypotensive activities of Metipranolol.Approved
DichlorvosDichlorvos may increase the bradycardic activities of Metipranolol.Vet Approved
DiclofenacDiclofenac may decrease the antihypertensive activities of Metipranolol.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Metipranolol.Approved
DiflunisalDiflunisal may decrease the antihypertensive activities of Metipranolol.Approved
DigitoxinMetipranolol may increase the bradycardic activities of Digitoxin.Approved
DigoxinDigoxin may increase the bradycardic activities of Metipranolol.Approved
DihydralazineMetipranolol may increase the hypotensive activities of Dihydralazine.Investigational
DihydroergotamineMetipranolol may increase the vasoconstricting activities of Dihydroergotamine.Approved
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Metipranolol.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Metipranolol is combined with Dinutuximab.Approved
DipyridamoleDipyridamole may increase the bradycardic activities of Metipranolol.Approved
DisopyramideDisopyramide may increase the bradycardic activities of Metipranolol.Approved
DonepezilDonepezil may increase the bradycardic activities of Metipranolol.Approved
DorzolamideDorzolamide may increase the hypotensive activities of Metipranolol.Approved
DoxazosinThe risk or severity of adverse effects can be increased when Doxazosin is combined with Metipranolol.Approved
DronedaroneDronedarone may increase the bradycardic activities of Metipranolol.Approved
DroxicamDroxicam may decrease the antihypertensive activities of Metipranolol.Approved
DuloxetineMetipranolol may increase the orthostatic hypotensive activities of Duloxetine.Approved
DuvelisibDuvelisib may decrease the antihypertensive activities of Metipranolol.Investigational
E6201E6201 may decrease the antihypertensive activities of Metipranolol.Investigational
EbselenEbselen may decrease the antihypertensive activities of Metipranolol.Investigational
EchothiophateEchothiophate may increase the bradycardic activities of Metipranolol.Approved
EdrophoniumEdrophonium may increase the bradycardic activities of Metipranolol.Approved
EfonidipineMetipranolol may increase the hypotensive activities of Efonidipine.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Metipranolol is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Metipranolol.Approved, Vet Approved
EnalaprilatMetipranolol may increase the hypotensive activities of Enalaprilat.Approved
EPIBATIDINEThe risk or severity of adverse effects can be increased when Metipranolol is combined with EPIBATIDINE.Experimental
EpirizoleEpirizole may decrease the antihypertensive activities of Metipranolol.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Eplerenone is combined with Metipranolol.Approved
EpoprostenolMetipranolol may increase the hypotensive activities of Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Metipranolol.Approved
Ergoloid mesylateMetipranolol may increase the vasoconstricting activities of Ergoloid mesylate.Approved
ErgonovineMetipranolol may increase the vasoconstricting activities of Ergonovine.Approved
ErgotamineMetipranolol may increase the vasoconstricting activities of Ergotamine.Approved
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Metipranolol.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Metipranolol.Approved
EtanerceptEtanercept may decrease the antihypertensive activities of Metipranolol.Approved, Investigational
EtodolacEtodolac may decrease the antihypertensive activities of Metipranolol.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may decrease the antihypertensive activities of Metipranolol.Approved
EtoperidoneThe serum concentration of Metipranolol can be increased when it is combined with Etoperidone.Approved
EtoricoxibEtoricoxib may decrease the antihypertensive activities of Metipranolol.Approved, Investigational
Evening primrose oilEvening primrose oil may decrease the antihypertensive activities of Metipranolol.Approved
exisulindexisulind may decrease the antihypertensive activities of Metipranolol.Investigational
FelodipineThe risk or severity of adverse effects can be increased when Felodipine is combined with Metipranolol.Approved, Investigational
FenbufenFenbufen may decrease the antihypertensive activities of Metipranolol.Approved
FenoldopamFenoldopam may increase the hypotensive activities of Metipranolol.Approved
FenoprofenFenoprofen may decrease the antihypertensive activities of Metipranolol.Approved
FentanylFentanyl may increase the bradycardic activities of Metipranolol.Approved, Illicit, Investigational, Vet Approved
FenthionFenthion may increase the bradycardic activities of Metipranolol.Vet Approved
FimasartanThe risk or severity of adverse effects can be increased when Metipranolol is combined with Fimasartan.Approved
FingolimodMetipranolol may increase the bradycardic activities of Fingolimod.Approved, Investigational
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Metipranolol.Approved, Withdrawn
FlunixinFlunixin may decrease the antihypertensive activities of Metipranolol.Vet Approved
FluoxetineThe serum concentration of Metipranolol can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FluphenazineFluphenazine may increase the hypotensive activities of Metipranolol.Approved
FlurbiprofenFlurbiprofen may decrease the antihypertensive activities of Metipranolol.Approved, Investigational
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Metipranolol.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Metipranolol.Approved, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Metipranolol.Approved, Vet Approved
GalantamineGalantamine may increase the bradycardic activities of Metipranolol.Approved
Gallamine TriethiodideGallamine Triethiodide may increase the bradycardic activities of Metipranolol.Approved
Ginkgo bilobaGinkgo biloba may increase the bradycardic activities of Metipranolol.Approved, Nutraceutical
GlibornurideMetipranolol may increase the hypoglycemic activities of Glibornuride.Withdrawn
GliclazideMetipranolol may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideMetipranolol may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideMetipranolol may increase the hypoglycemic activities of Glipizide.Approved
GliquidoneMetipranolol may increase the hypoglycemic activities of Gliquidone.Approved
GlisoxepideMetipranolol may increase the hypoglycemic activities of Glisoxepide.Approved
GlyburideMetipranolol may increase the hypoglycemic activities of Glyburide.Approved
GTS-21The risk or severity of adverse effects can be increased when Metipranolol is combined with GTS-21.Investigational
GuanabenzGuanabenz may increase the hypotensive activities of Metipranolol.Approved
GuanadrelGuanadrel may increase the hypotensive activities of Metipranolol.Approved
GuanethidineGuanethidine may increase the hypotensive activities of Metipranolol.Approved
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Metipranolol.Approved, Investigational
HalothaneThe risk or severity of adverse effects can be increased when Metipranolol is combined with Halothane.Approved, Vet Approved
HexamethoniumMetipranolol may increase the hypotensive activities of Hexamethonium.Experimental
HexobarbitalHexobarbital may increase the hypotensive activities of Metipranolol.Approved
HigenamineHigenamine may decrease the antihypertensive activities of Metipranolol.Investigational
HMPL-004HMPL-004 may decrease the antihypertensive activities of Metipranolol.Investigational
Huperzine AHuperzine A may increase the bradycardic activities of Metipranolol.Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Metipranolol.Approved
HydralazineThe risk or severity of adverse effects can be increased when Metipranolol is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Metipranolol.Approved, Vet Approved
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Metipranolol.Approved
HydroxychloroquineThe metabolism of Metipranolol can be decreased when combined with Hydroxychloroquine.Approved
IbuprofenIbuprofen may decrease the antihypertensive activities of Metipranolol.Approved
IbuproxamIbuproxam may decrease the antihypertensive activities of Metipranolol.Withdrawn
IcatibantIcatibant may decrease the antihypertensive activities of Metipranolol.Approved
IloprostIloprost may increase the hypotensive activities of Metipranolol.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Metipranolol is combined with Imidapril.Investigational
ImipramineThe risk or severity of adverse effects can be increased when Metipranolol is combined with Imipramine.Approved
IndalpineThe serum concentration of Metipranolol can be increased when it is combined with Indalpine.Investigational, Withdrawn
IndapamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Metipranolol.Approved
IndenololMetipranolol may increase the hypotensive activities of Indenolol.Withdrawn
IndomethacinIndomethacin may decrease the antihypertensive activities of Metipranolol.Approved, Investigational
IndoprofenIndoprofen may decrease the antihypertensive activities of Metipranolol.Withdrawn
IndoraminMetipranolol may increase the hypotensive activities of Indoramin.Withdrawn
IproclozideIproclozide may increase the hypotensive activities of Metipranolol.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Metipranolol.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Metipranolol.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Metipranolol.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Metipranolol is combined with Isoflurane.Approved, Vet Approved
IsoflurophateIsoflurophate may increase the bradycardic activities of Metipranolol.Approved, Withdrawn
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Metipranolol.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Metipranolol.Approved
IsoxicamIsoxicam may decrease the antihypertensive activities of Metipranolol.Withdrawn
IsoxsuprineThe risk or severity of adverse effects can be increased when Metipranolol is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Metipranolol.Approved
IvabradineMetipranolol may increase the bradycardic activities of Ivabradine.Approved
KebuzoneKebuzone may decrease the antihypertensive activities of Metipranolol.Experimental
KetanserinMetipranolol may increase the hypotensive activities of Ketanserin.Investigational
KetoprofenKetoprofen may decrease the antihypertensive activities of Metipranolol.Approved, Vet Approved
KetorolacKetorolac may decrease the antihypertensive activities of Metipranolol.Approved
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Metipranolol.Approved
LacidipineMetipranolol may increase the hypotensive activities of Lacidipine.Approved
LacosamideMetipranolol may increase the atrioventricular blocking (AV block) activities of Lacosamide.Approved
LanreotideMetipranolol may increase the bradycardic activities of Lanreotide.Approved
LatanoprostLatanoprost may increase the hypotensive activities of Metipranolol.Approved, Investigational
LeflunomideLeflunomide may decrease the antihypertensive activities of Metipranolol.Approved, Investigational
LercanidipineLercanidipine may increase the hypotensive activities of Metipranolol.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Levobunolol is combined with Metipranolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Metipranolol is combined with Levobupivacaine.Approved
LevodopaMetipranolol may increase the orthostatic hypotensive activities of Levodopa.Approved
LevomilnacipranThe serum concentration of Metipranolol can be increased when it is combined with Levomilnacipran.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Metipranolol is combined with Levosimendan.Approved, Investigational
LidocaineThe serum concentration of Lidocaine can be increased when it is combined with Metipranolol.Approved, Vet Approved
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Metipranolol.Approved, Investigational
LisofyllineLisofylline may decrease the antihypertensive activities of Metipranolol.Investigational
LobelineThe risk or severity of adverse effects can be increased when Metipranolol is combined with Lobeline.Investigational
LofexidineMetipranolol may increase the hypotensive activities of Lofexidine.Approved, Investigational
LornoxicamLornoxicam may decrease the antihypertensive activities of Metipranolol.Approved
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Metipranolol.Approved
LoxoprofenLoxoprofen may decrease the antihypertensive activities of Metipranolol.Approved
LucinactantMetipranolol may increase the bradycardic activities of Lucinactant.Approved
LumiracoxibLumiracoxib may decrease the antihypertensive activities of Metipranolol.Approved, Investigational
MacitentanMetipranolol may increase the hypotensive activities of Macitentan.Approved
Magnesium salicylateMagnesium salicylate may decrease the antihypertensive activities of Metipranolol.Approved
MalathionMalathion may increase the bradycardic activities of Metipranolol.Approved, Investigational
ManidipineMetipranolol may increase the hypotensive activities of Manidipine.Approved
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Metipranolol.Approved, Investigational
MasoprocolMasoprocol may decrease the antihypertensive activities of Metipranolol.Approved
MebanazineMebanazine may increase the hypotensive activities of Metipranolol.Withdrawn
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Metipranolol.Approved
Meclofenamic acidMeclofenamic acid may decrease the antihypertensive activities of Metipranolol.Approved, Vet Approved
Mefenamic acidMefenamic acid may decrease the antihypertensive activities of Metipranolol.Approved
MefloquineMefloquine may increase the bradycardic activities of Metipranolol.Approved
MeloxicamMeloxicam may decrease the antihypertensive activities of Metipranolol.Approved, Vet Approved
MemantineMemantine may increase the bradycardic activities of Metipranolol.Approved, Investigational
MepivacaineThe serum concentration of Mepivacaine can be increased when it is combined with Metipranolol.Approved, Vet Approved
MesalazineMesalazine may decrease the antihypertensive activities of Metipranolol.Approved
MesoridazineMesoridazine may increase the hypotensive activities of Metipranolol.Approved
MetamizoleMetamizole may decrease the antihypertensive activities of Metipranolol.Withdrawn
MethacholineThe risk or severity of adverse effects can be increased when Metipranolol is combined with Methacholine.Approved
Methanesulfonyl FluorideMethanesulfonyl Fluoride may increase the bradycardic activities of Metipranolol.Investigational
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Metipranolol.Approved
MethohexitalMethohexital may increase the hypotensive activities of Metipranolol.Approved
MethotrimeprazineMethotrimeprazine may increase the hypotensive activities of Metipranolol.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Metipranolol.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Methyldopa is combined with Metipranolol.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Metipranolol.Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Metipranolol.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Metipranolol.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Metipranolol.Approved
MetoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Metipranolol.Approved, Investigational
MetyrosineMetipranolol may increase the hypotensive activities of Metyrosine.Approved
MibefradilMetipranolol may increase the hypotensive activities of Mibefradil.Withdrawn
MidodrineMetipranolol may increase the bradycardic activities of Midodrine.Approved
MilnacipranThe serum concentration of Metipranolol can be increased when it is combined with Milnacipran.Approved
MinaprineMinaprine may increase the hypotensive activities of Metipranolol.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Metipranolol.Approved
MizoribineMizoribine may decrease the antihypertensive activities of Metipranolol.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Metipranolol.Approved
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Metipranolol.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Metipranolol.Approved
MoricizineMoricizine may increase the hypotensive activities of Metipranolol.Approved, Withdrawn
MorphineThe risk or severity of adverse effects can be increased when Metipranolol is combined with Morphine.Approved, Investigational
MoxonidineMetipranolol may increase the hypotensive activities of Moxonidine.Approved
Mycophenolate mofetilMycophenolate mofetil may decrease the antihypertensive activities of Metipranolol.Approved, Investigational
Mycophenolic acidMycophenolic acid may decrease the antihypertensive activities of Metipranolol.Approved
NabiloneThe risk or severity of adverse effects can be increased when Metipranolol is combined with Nabilone.Approved, Investigational
NabumetoneNabumetone may decrease the antihypertensive activities of Metipranolol.Approved
NadololThe risk or severity of adverse effects can be increased when Nadolol is combined with Metipranolol.Approved
NafamostatNafamostat may decrease the antihypertensive activities of Metipranolol.Investigational
NaftifineNaftifine may decrease the antihypertensive activities of Metipranolol.Approved
NaftopidilMetipranolol may increase the hypotensive activities of Naftopidil.Investigational
NaproxenNaproxen may decrease the antihypertensive activities of Metipranolol.Approved, Vet Approved
NCX 4016NCX 4016 may decrease the antihypertensive activities of Metipranolol.Investigational
NebivololThe risk or severity of adverse effects can be increased when Metipranolol is combined with Nebivolol.Approved, Investigational
NefazodoneThe serum concentration of Metipranolol can be increased when it is combined with Nefazodone.Approved, Withdrawn
NeostigmineNeostigmine may increase the bradycardic activities of Metipranolol.Approved, Vet Approved
NepafenacNepafenac may decrease the antihypertensive activities of Metipranolol.Approved
NesiritideThe risk or severity of adverse effects can be increased when Metipranolol is combined with Nesiritide.Approved, Investigational
NialamideNialamide may increase the hypotensive activities of Metipranolol.Withdrawn
NicardipineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Metipranolol.Approved
NicorandilNicorandil may increase the hypotensive activities of Metipranolol.Approved
NicotineThe risk or severity of adverse effects can be increased when Metipranolol is combined with Nicotine.Approved
Nicotine bitartrateThe risk or severity of adverse effects can be increased when Metipranolol is combined with Nicotine bitartrate.Approved
NifedipineNifedipine may increase the hypotensive activities of Metipranolol.Approved
Niflumic AcidNiflumic Acid may decrease the antihypertensive activities of Metipranolol.Approved
NiguldipineMetipranolol may increase the hypotensive activities of Niguldipine.Experimental
NilvadipineMetipranolol may increase the hypotensive activities of Nilvadipine.Approved
NimesulideNimesulide may decrease the antihypertensive activities of Metipranolol.Approved, Withdrawn
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Metipranolol.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Metipranolol.Approved
NitrendipineNitrendipine may increase the hypotensive activities of Metipranolol.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Metipranolol is combined with Nitric Oxide.Approved
NitroaspirinNitroaspirin may decrease the antihypertensive activities of Metipranolol.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Metipranolol.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Metipranolol.Approved
ObinutuzumabMetipranolol may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Metipranolol.Withdrawn
OctreotideOctreotide may increase the bradycardic activities of Metipranolol.Approved, Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Metipranolol.Approved, Investigational
OlopatadineOlopatadine may decrease the antihypertensive activities of Metipranolol.Approved
OlsalazineOlsalazine may decrease the antihypertensive activities of Metipranolol.Approved
OmapatrilatOmapatrilat may increase the hypotensive activities of Metipranolol.Investigational
OrgoteinOrgotein may decrease the antihypertensive activities of Metipranolol.Vet Approved
OuabainMetipranolol may increase the bradycardic activities of Ouabain.Approved
OxaprozinOxaprozin may decrease the antihypertensive activities of Metipranolol.Approved
OxprenololMetipranolol may increase the hypotensive activities of Oxprenolol.Approved
OxyphenbutazoneOxyphenbutazone may decrease the antihypertensive activities of Metipranolol.Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Metipranolol is combined with Paclitaxel.Approved, Vet Approved
PapaverineThe risk or severity of adverse effects can be increased when Papaverine is combined with Metipranolol.Approved
ParecoxibParecoxib may decrease the antihypertensive activities of Metipranolol.Approved
PargylinePargyline may increase the hypotensive activities of Metipranolol.Approved
ParoxetineThe serum concentration of Metipranolol can be increased when it is combined with Paroxetine.Approved, Investigational
PasireotideMetipranolol may increase the bradycardic activities of Pasireotide.Approved
PenbutololThe risk or severity of adverse effects can be increased when Metipranolol is combined with Penbutolol.Approved, Investigational
PentobarbitalPentobarbital may increase the hypotensive activities of Metipranolol.Approved, Vet Approved
PentoliniumPentolinium may increase the hypotensive activities of Metipranolol.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Metipranolol.Approved, Investigational
PerazinePerazine may increase the hypotensive activities of Metipranolol.Investigational
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Metipranolol.Approved
PerphenazinePerphenazine may increase the hypotensive activities of Metipranolol.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Metipranolol.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Metipranolol.Withdrawn
PhenobarbitalPhenobarbital may increase the hypotensive activities of Metipranolol.Approved
PhenoxybenzaminePhenoxybenzamine may increase the hypotensive activities of Metipranolol.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Metipranolol.Withdrawn
PhentolaminePhentolamine may increase the hypotensive activities of Metipranolol.Approved
PhenylbutazonePhenylbutazone may decrease the antihypertensive activities of Metipranolol.Approved, Vet Approved
PhysostigminePhysostigmine may increase the bradycardic activities of Metipranolol.Approved
PilocarpineThe risk or severity of adverse effects can be increased when Metipranolol is combined with Pilocarpine.Approved
PimecrolimusPimecrolimus may decrease the antihypertensive activities of Metipranolol.Approved, Investigational
PinacidilMetipranolol may increase the hypotensive activities of Pinacidil.Withdrawn
PindololThe risk or severity of adverse effects can be increased when Pindolol is combined with Metipranolol.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Metipranolol is combined with Pipamperone.Approved
PirfenidonePirfenidone may decrease the antihypertensive activities of Metipranolol.Investigational
PirlindolePirlindole may increase the hypotensive activities of Metipranolol.Approved
PiroxicamPiroxicam may decrease the antihypertensive activities of Metipranolol.Approved, Investigational
PivhydrazinePivhydrazine may increase the hypotensive activities of Metipranolol.Withdrawn
PolythiazideMetipranolol may increase the hypotensive activities of Polythiazide.Approved
Poractant alfaMetipranolol may increase the bradycardic activities of Poractant alfa.Approved
PramipexoleThe risk or severity of adverse effects can be increased when Metipranolol is combined with Pramipexole.Approved, Investigational
PrazosinThe risk or severity of adverse effects can be increased when Prazosin is combined with Metipranolol.Approved
PrimaquineThe metabolism of Metipranolol can be decreased when combined with Primaquine.Approved
PrimidonePrimidone may increase the hypotensive activities of Metipranolol.Approved, Vet Approved
ProchlorperazineProchlorperazine may increase the hypotensive activities of Metipranolol.Approved, Vet Approved
PromazinePromazine may increase the hypotensive activities of Metipranolol.Approved, Vet Approved
PromethazinePromethazine may increase the hypotensive activities of Metipranolol.Approved
PropacetamolPropacetamol may decrease the antihypertensive activities of Metipranolol.Approved
PropafenoneThe serum concentration of Metipranolol can be increased when it is combined with Propafenone.Approved
PropiopromazinePropiopromazine may increase the hypotensive activities of Metipranolol.Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Metipranolol is combined with Propofol.Approved, Investigational, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Propranolol is combined with Metipranolol.Approved, Investigational
PTC299PTC299 may decrease the antihypertensive activities of Metipranolol.Investigational
PyridostigminePyridostigmine may increase the bradycardic activities of Metipranolol.Approved
QuetiapineThe risk or severity of adverse effects can be increased when Metipranolol is combined with Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Metipranolol.Approved, Investigational
QuinineQuinine may increase the hypotensive activities of Metipranolol.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Metipranolol.Approved
RasagilineRasagiline may increase the hypotensive activities of Metipranolol.Approved
RegorafenibRegorafenib may increase the bradycardic activities of Metipranolol.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Metipranolol is combined with Remifentanil.Approved
RemikirenRemikiren may increase the hypotensive activities of Metipranolol.Approved
RescinnamineMetipranolol may increase the hypotensive activities of Rescinnamine.Approved
ReserpineReserpine may increase the hypotensive activities of Metipranolol.Approved
ResveratrolResveratrol may decrease the antihypertensive activities of Metipranolol.Experimental, Investigational
RifampicinThe serum concentration of Metipranolol can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Metipranolol can be decreased when it is combined with Rifapentine.Approved
RilmenidineMetipranolol may increase the hypotensive activities of Rilmenidine.Investigational
RiociguatThe risk or severity of adverse effects can be increased when Metipranolol is combined with Riociguat.Approved
RisperidoneMetipranolol may increase the hypotensive activities of Risperidone.Approved, Investigational
RituximabMetipranolol may increase the hypotensive activities of Rituximab.Approved
RivastigmineRivastigmine may increase the bradycardic activities of Metipranolol.Approved, Investigational
RofecoxibRofecoxib may decrease the antihypertensive activities of Metipranolol.Investigational, Withdrawn
RopiniroleThe risk or severity of adverse effects can be increased when Metipranolol is combined with Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Metipranolol is combined with Ropivacaine.Approved
RotigotineThe risk or severity of adverse effects can be increased when Metipranolol is combined with Rotigotine.Approved
RuxolitinibRuxolitinib may increase the bradycardic activities of Metipranolol.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Metipranolol is combined with Sacubitril.Approved
SafrazineSafrazine may increase the hypotensive activities of Metipranolol.Withdrawn
SalicylamideSalicylamide may decrease the antihypertensive activities of Metipranolol.Approved
Salicylic acidSalicylic acid may decrease the antihypertensive activities of Metipranolol.Approved, Vet Approved
SalsalateSalsalate may decrease the antihypertensive activities of Metipranolol.Approved
SaprisartanMetipranolol may increase the hypotensive activities of Saprisartan.Experimental
SecobarbitalSecobarbital may increase the hypotensive activities of Metipranolol.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Metipranolol.Approved, Investigational, Vet Approved
SelexipagMetipranolol may increase the hypotensive activities of Selexipag.Approved
SeratrodastSeratrodast may decrease the antihypertensive activities of Metipranolol.Approved, Investigational
SertralineThe serum concentration of Metipranolol can be increased when it is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Metipranolol is combined with Sevoflurane.Approved, Vet Approved
SildenafilSildenafil may increase the antihypertensive activities of Metipranolol.Approved, Investigational
SitaxentanMetipranolol may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium NitriteThe risk or severity of adverse effects can be increased when Metipranolol is combined with Sodium Nitrite.Approved
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Metipranolol.Approved
SpiraprilMetipranolol may increase the hypotensive activities of Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Metipranolol.Approved
SRT501SRT501 may decrease the antihypertensive activities of Metipranolol.Investigational
StreptokinaseThe risk or severity of adverse effects can be increased when Metipranolol is combined with Streptokinase.Approved
SufentanilSufentanil may increase the bradycardic activities of Metipranolol.Approved, Investigational
SulfasalazineSulfasalazine may decrease the antihypertensive activities of Metipranolol.Approved
SulindacSulindac may decrease the antihypertensive activities of Metipranolol.Approved
SuprofenSuprofen may decrease the antihypertensive activities of Metipranolol.Approved, Withdrawn
TacrineTacrine may increase the bradycardic activities of Metipranolol.Withdrawn
TadalafilTadalafil may increase the antihypertensive activities of Metipranolol.Approved, Investigational
TamsulosinThe risk or severity of adverse effects can be increased when Metipranolol is combined with Tamsulosin.Approved, Investigational
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Metipranolol.Approved, Investigational
TemocaprilMetipranolol may increase the hypotensive activities of Temocapril.Experimental, Investigational
TenoxicamTenoxicam may decrease the antihypertensive activities of Metipranolol.Approved
TepoxalinTepoxalin may decrease the antihypertensive activities of Metipranolol.Vet Approved
TerazosinThe risk or severity of adverse effects can be increased when Terazosin is combined with Metipranolol.Approved
TeriflunomideTeriflunomide may decrease the antihypertensive activities of Metipranolol.Approved
TerlipressinMetipranolol may increase the hypotensive activities of Terlipressin.Approved, Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Metipranolol is combined with Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThiamylal may increase the hypotensive activities of Metipranolol.Approved, Vet Approved
ThiethylperazineThiethylperazine may increase the hypotensive activities of Metipranolol.Withdrawn
ThiopentalThiopental may increase the hypotensive activities of Metipranolol.Approved, Vet Approved
ThioridazineThioridazine may increase the hypotensive activities of Metipranolol.Approved
Tiaprofenic acidTiaprofenic acid may decrease the antihypertensive activities of Metipranolol.Approved
TiboloneMetipranolol may increase the hypotensive activities of Tibolone.Approved
TicrynafenMetipranolol may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Metipranolol.Approved
TinoridineTinoridine may decrease the antihypertensive activities of Metipranolol.Investigational
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Metipranolol.Approved
TofacitinibTofacitinib may increase the bradycardic activities of Metipranolol.Approved, Investigational
TolazamideMetipranolol may increase the hypoglycemic activities of Tolazamide.Approved
TolazolineTolazoline may increase the hypotensive activities of Metipranolol.Approved, Vet Approved
TolbutamideMetipranolol may increase the hypoglycemic activities of Tolbutamide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Metipranolol is combined with Tolcapone.Approved, Withdrawn
Tolfenamic AcidTolfenamic Acid may decrease the antihypertensive activities of Metipranolol.Approved
TolmetinTolmetin may decrease the antihypertensive activities of Metipranolol.Approved
ToloxatoneToloxatone may increase the hypotensive activities of Metipranolol.Approved
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Metipranolol.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Metipranolol.Approved
TranilastTranilast may decrease the antihypertensive activities of Metipranolol.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Metipranolol.Experimental
TranylcypromineTranylcypromine may increase the hypotensive activities of Metipranolol.Approved
TravoprostTravoprost may increase the hypotensive activities of Metipranolol.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Metipranolol.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Metipranolol is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Metipranolol.Approved
TrichlorfonTrichlorfon may increase the bradycardic activities of Metipranolol.Vet Approved
TrichlormethiazideTrichlormethiazide may increase the hypotensive activities of Metipranolol.Approved, Vet Approved
TrifluoperazineTrifluoperazine may increase the hypotensive activities of Metipranolol.Approved
TriflupromazineTriflupromazine may increase the hypotensive activities of Metipranolol.Approved, Vet Approved
TrimazosinMetipranolol may increase the hypotensive activities of Trimazosin.Experimental
TrimethaphanTrimethaphan may increase the hypotensive activities of Metipranolol.Approved
Trisalicylate-cholineTrisalicylate-choline may decrease the antihypertensive activities of Metipranolol.Approved
TubocurarineTubocurarine may increase the bradycardic activities of Metipranolol.Approved
UdenafilUdenafil may increase the antihypertensive activities of Metipranolol.Approved, Investigational
UnoprostoneMetipranolol may increase the hypotensive activities of Unoprostone.Approved
ValdecoxibValdecoxib may decrease the antihypertensive activities of Metipranolol.Investigational, Withdrawn
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Metipranolol.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Metipranolol.Approved
VareniclineThe risk or severity of adverse effects can be increased when Metipranolol is combined with Varenicline.Approved, Investigational
VenlafaxineThe serum concentration of Metipranolol can be increased when it is combined with Venlafaxine.Approved
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Metipranolol.Approved
VinpocetineMetipranolol may increase the hypotensive activities of Vinpocetine.Investigational
XylometazolineMetipranolol may increase the hypotensive activities of Xylometazoline.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Metipranolol.Approved, Vet Approved
ZaltoprofenZaltoprofen may decrease the antihypertensive activities of Metipranolol.Approved
ZileutonZileuton may decrease the antihypertensive activities of Metipranolol.Approved, Investigational, Withdrawn
ZimelidineThe serum concentration of Metipranolol can be increased when it is combined with Zimelidine.Withdrawn
ZomepiracZomepirac may decrease the antihypertensive activities of Metipranolol.Withdrawn
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesC07BA68S01ED54S01ED04
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.8638
Blood Brain Barrier-0.9906
Caco-2 permeable-0.5988
P-glycoprotein substrateSubstrate0.6335
P-glycoprotein inhibitor INon-inhibitor0.7599
P-glycoprotein inhibitor IINon-inhibitor0.8296
Renal organic cation transporterNon-inhibitor0.9097
CYP450 2C9 substrateNon-substrate0.8014
CYP450 2D6 substrateSubstrate0.5086
CYP450 3A4 substrateNon-substrate0.6564
CYP450 1A2 substrateNon-inhibitor0.6333
CYP450 2C9 inhibitorNon-inhibitor0.8721
CYP450 2D6 inhibitorNon-inhibitor0.7104
CYP450 2C19 inhibitorNon-inhibitor0.9547
CYP450 3A4 inhibitorNon-inhibitor0.8282
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9528
Ames testNon AMES toxic0.9219
CarcinogenicityNon-carcinogens0.9205
BiodegradationNot ready biodegradable0.7546
Rat acute toxicity2.1686 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9794
hERG inhibition (predictor II)Non-inhibitor0.7745
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Solution / dropsOphthalmic3 mg/mL
Prices
Unit descriptionCostUnit
Optipranolol 0.3% Solution 10ml Bottle42.99USD bottle
Optipranolol 0.3% Solution 5ml Bottle25.99USD bottle
Optipranolol 0.3% eye drops5.08USD ml
Metipranolol 0.3% eye drops3.55USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point105-107 °CPhysProp
water solubility589 mg/LNot Available
logP2.66MANNHOLD,R ET AL. (1990)
Predicted Properties
PropertyValueSource
Water Solubility0.173 mg/mLALOGPS
logP2.13ALOGPS
logP2.74ChemAxon
logS-3.2ALOGPS
pKa (Strongest Acidic)14.09ChemAxon
pKa (Strongest Basic)9.67ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area67.79 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity86.63 m3·mol-1ChemAxon
Polarizability35.85 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenol esters. These are aromatic compounds containing a benzene ring substituted by a hydroxyl group and an ester group.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassPhenol esters
Direct ParentPhenol esters
Alternative Parents
Substituents
  • Phenol ester
  • Phenol ether
  • Alkyl aryl ether
  • Acetate salt
  • Secondary alcohol
  • Carboxylic acid ester
  • 1,2-aminoalcohol
  • Secondary amine
  • Ether
  • Secondary aliphatic amine
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Alcohol
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Receptor signaling protein activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately equal affinity. Mediates Ras activation through G(s)-alpha- and cAMP-mediated signaling.
Gene Name:
ADRB1
Uniprot ID:
P08588
Molecular Weight:
51322.1 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Drimal J, Knezl V, Magna D, Strizova K: External transport of beta-adrenergic binding sites in ischemic myocardium. Gen Physiol Biophys. 1987 Dec;6(6):583-91. [PubMed:2895037 ]
  4. Arai K, Wood JP, Osborne NN: Beta-adrenergic receptor agonists and antagonists counteract LPS-induced neuronal death in retinal cultures by different mechanisms. Brain Res. 2003 Sep 26;985(2):176-86. [PubMed:12967722 ]
  5. Bilcikova L, Bauer V, Kolena J: The action of adrenoceptor agonists and antagonists on the guinea pig and dog trachea. Gen Physiol Biophys. 1987 Feb;6(1):87-101. [PubMed:2885244 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Protein homodimerization activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately 30-fold greater affinity than it does norepinephrine.
Gene Name:
ADRB2
Uniprot ID:
P07550
Molecular Weight:
46458.32 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Drimal J, Knezl V, Magna D, Strizova K: External transport of beta-adrenergic binding sites in ischemic myocardium. Gen Physiol Biophys. 1987 Dec;6(6):583-91. [PubMed:2895037 ]
  4. Noack E: [Antiglaucomatous effectiveness of beta receptor blockers with special reference to metipranolol]. Klin Monbl Augenheilkd. 1986 Jul;189(1):1-3. [PubMed:2876128 ]
  5. Arai K, Wood JP, Osborne NN: Beta-adrenergic receptor agonists and antagonists counteract LPS-induced neuronal death in retinal cultures by different mechanisms. Brain Res. 2003 Sep 26;985(2):176-86. [PubMed:12967722 ]
  6. Bilcikova L, Bauer V, Kolena J: The action of adrenoceptor agonists and antagonists on the guinea pig and dog trachea. Gen Physiol Biophys. 1987 Feb;6(1):87-101. [PubMed:2885244 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23